patient

Key Points VEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy. The VEN plus HMA combination allows for a safe and effective bridging to allo-HCT. Abstract The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with…

Recent advances in acute myeloid leukemia (AML) come from studies investigating younger (age<60 years) adults or older (age≥75 years) or less fit adults. Uncertainty exists for the management of otherwise healthy adults with AML in their 60s and 70s, which also represents a…

Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show “robust clinical activity” in patients newly diagnosed with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML)…

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer. The studies — both conducted in…

In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that iron overload (IOL), accumulated via a mutation in the iron importer ferroportin, accelerates the myelodysplastic syndrome (MDS) phenotype, leading to exacerbation of marrow failure, inferior…

Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have…

Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with graft-versus-host disease (GVHD), according to a news release from the…

Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in red blood cell (RBC) transfusion burden and hemoglobin levels among study participants. The link goes to a video presentation.